# Пов'язані статті щодо Rejuvenation

Центр новин HTX надає останні статті та поглиблений аналіз на тему "Rejuvenation", що охоплює ринкові тренди, оновлення проєктів, технологічні розробки та регуляторну політику в криптоіндустрії.

The Founder of Coinbase Is Going to Research Immortality

Coinbase founder Brian Armstrong has co-founded NewLimit, a longevity biotech startup, which just raised $435 million in a Series C funding round led by Peter Thiel’s Founders Fund. The round values the company at $3.1 billion, more than triple its valuation from a year ago. NewLimit is developing drugs aimed at reversing cellular aging to extend human healthspan. Its approach builds on Nobel Prize-winning research on cellular reprogramming (Yamanaka factors), with a focus on identifying specific gene combinations that can restore younger cell function. The company plans to begin human clinical trials next year, initially targeting alcohol-related liver disease as a form of accelerated aging. Founded in 2021 by Armstrong alongside biotech investor Blake Byers and scientist Jacob Kimmel, NewLimit has now raised over $700 million across multiple rounds. It joins a growing field of well-funded longevity ventures backed by tech billionaires, including Sam Altman’s Retro Biosciences and Jeff Bezos-backed Altos Labs, reflecting a surge of interest in using science to combat aging and extend healthy lifespan.

marsbit15 год тому

The Founder of Coinbase Is Going to Research Immortality

marsbit15 год тому

Coinbase Founder Is Now Researching Immortality

Coinbase Founder Invests in the "Fountain of Youth": NewLimit's $435M Funding to Reverse Aging Brian Armstrong, co-founder and CEO of Coinbase, is now targeting a new frontier: human longevity. His biotech startup, NewLimit, has just raised $435 million in a Series C round led by Peter Thiel’s Founders Fund, valuing the company at $3.1 billion. The funding will advance its mission to develop therapies that slow or even reverse cellular aging, with its first drug targeting alcohol-related liver disease set to enter clinical trials next year. Founded in 2021 by Armstrong, former GV partner Blake Byers, and stem cell biologist Jacob Kimmel, NewLimit builds on Nobel Prize-winning research by Shinya Yamanaka, who discovered that adult cells can be reprogrammed to a younger state. NewLimit’s approach focuses on identifying specific gene combinations to reset the "epigenetic age" of cells, aiming first to treat diseases viewed as accelerated aging before broadening its applications. The company joins a growing field of longevity startups backed by tech billionaires, including Sam Altman’s investment in Retro Biosciences and Jeff Bezos’s support for Altos Labs. For these ultra-wealthy backers, conquering aging represents the ultimate investment—extending the one resource even immense wealth cannot buy: time.

Odaily星球日报15 год тому

Coinbase Founder Is Now Researching Immortality

Odaily星球日报15 год тому

活动图片

Market Analysis

Indepth Research